GLASGOW, Scotland (PRWEB) February 13, 2018 -- Immunotherapy company TC BioPharm Ltd (TCB) announced opening of a new office in Japan to continue expansion of its Asian operations.
Developing innovative CAR-T-based approaches to treat cancer, TC BioPharm has an established history of working closely with Japanese biotech and pharmaceutical companies. TCB was founded by Dr Michael Leek in Glasgow, 2014.
Soon after commencing operations, Tokyo-based biotech company Medinet made an initial investment to assist progress to UK-based clinical studies.
Since incorporation, TCB has also worked closely with Cell Science & Technology Institute Inc. (a subsidiary of the NIPRO Corporation, Osaka), who exclusively developed specialised culture media to assist manufacture of ImmuniCAR® and other cell-based therapies being developed by TCB.
In 2017, as part of a $8m equity round, TCB obtained its first significant investment from a major pharmaceutical company – the NIPRO Corporation (Osaka) who along with the Scottish Investment Bank contributed the majority of TCB’s series-A fundraising.
More recently, the NIPRO Corporation announced that they had formed a strategic collaboration to co-develop a novel immunotherapy product using TCB’s safe CAR-T platform, based on unique properties of modified gamma delta T cells to selectively target cancer whilst leaving healthy cells untouched. TCB intends to use this novel platform to develop new CAR-based immunotherapies, with the aim of treating a broad range of cancers and major viral disease.
From 14th February 2018, TCB’s Japanese operations will be located at the ”Kanagawa Life Innovation Center” Tonomachi, Kawasaki City, Kanagawa Prefecture. Opposite Tokyo’s Haneda International airport, the biotech cluster at Tonomachi has been created for businesses to devise solutions to global issues in the life sciences sector. The Japanese Government has designated KING SKYFRONT to be a special zone for international development, and is the flagship science and technology innovation hub of Kawasaki City.
Commenting on TCB’s occupancy at the Kawasaki KING SKYFRONT, Dr Michael Leek, TCB’s Chief Executive and Founder said, “We have been working closely with Japanese companies since TC BioPharm commenced operations in 2014, I’m delighted that we now have a physical presence at the Kanagawa Life Innovation Center in Japan as we look to future clinical and commercial collaborations with the ultimate aim of improving patient health and quality of life.”
Assisting TCB to find an ideal location in Japan, the Company received extensive guidance from Scottish Development International (international arm of the Scottish Government and Scottish Enterprise). Remarking on this significant outward investment for TCB and Scotland, Mr. Yuji Kuroiwa, Governor of Kanagawa Prefecture, noted, “We all welcome TC BioPharm’s decision to locate in Kanagawa Life Innovation Center (LIC). I am filled with deep emotion that the presence of SDI in LIC has led to an outcome, TCB, a leading company in cell therapy, deciding to locate in LIC. Kanagawa Prefectural Government is ready to provide positive support to TCB’s projects. I truly hope the development of TCB’s RM related projects in Japan.”
Chief Business Officer Dr Artin Moussavi added, “Japan is a key market for TC BioPharm and having a base there is the next logical step for us. We already have strong partnerships in Japan and this opening furthermore demonstrates our long-term vision and investment to developing a major immunotherapy business in Japan and Asia.”
For more information regarding TC BioPharm, please contact Suzanne Clark at Smarts Communicate:
suzanne.clark(at)smartscommunicate(dot)com / 0141 222 2040 / 07970 834354
Note to Editors:
Headquartered at the Pentlands Science Park outside Edinburgh, TCB is registered in Scotland (SC 453579). Becoming operational from February 2014, the Company is developing ImmuniCell® an autologous anti-cancer immunotherapy which involves expansion of gamma-delta T cells over several weeks - formulating a treatment for a wide-variety of different tumour types. In January 2015, TCB’s cell therapy manufacturing facility at Maxim Park, Glasgow was awarded a Manufacturer's Authorisation for Investigational Medicinal Products MIA (IMP) which permits manufacture and release of Advanced Therapy Medicinal Products (ATMPs) for use in clinical trials. Further to obtaining an MHRA manufacturing license, TCB was granted a Clinical Trial Authorisation (CTA) by the MHRA in September 2015. Phase II clinical studies are ongoing throughout the UK.
Scottish Enterprise is Scotland's main economic development agency and aims to deliver a significant, lasting effect on the Scottish economy. Our role is to help identify and exploit the best opportunities for economic growth. We support ambitious Scottish companies to compete within the global marketplace and help build Scotland’s globally competitive sectors. We also work with a range of partners in the public and private sectors to attract new investment to Scotland and to help create a world-class business environment.
Artin Moussavi, TC BioPharm, http://www.tcbiopharm.com, +44 1414337557, [email protected]
Share this article